Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Econ ; 13(3): 492-9, 2010.
Article in English | MEDLINE | ID: mdl-20670159

ABSTRACT

BACKGROUND: Pseudomonas aeruginosa (PA) is the most common airway pathogen in cystic fibrosis (CF) patients. The objective of this analysis was to determine the costs of managing PA infection in CF patients with a chronic regimen of tobramycin inhalation solution (TIS). METHODS: A budget impact model of CF patients was developed to evaluate the costs of TIS from a US managed-care organization (MCO) perspective. The Microsoft Excel model compared TIS treatment plus standard care with standard care alone over a 4-year time horizon and included the cost of drugs, medical care, and annual probabilities of hospitalization and IV anti-pseudomonal (anti-PA) antibiotics administration. RESULTS: For an MCO with 5,000,000 members, 389 members 6 years of age or older were estimated to have CF, and 218 (56%) had PA infection. Assuming that use of TIS increased from 20% to 25%, the 1-year budget increased $231,251 or from $0.049 to $0.053 per member per month (PMPM). The net drug budget increase was $243,919, while medical costs associated with exacerbation management decreased $12,669 over the first year. Increasing utilization of TIS, from 20% to 40% over 4 years resulted in an incremental overall budget increase of $925,002, a 3% decrease in hospitalizations, and a 4% decrease in administrations of IV anti-PA antibiotics. These reductions translated to a medical care cost saving of $50,676 over 4 years. Limitations of this study include that the clinical data for the model are from clinical trials conducted in 1996 and the estimation of TIS use for CF patients with chronic PA infections can be impacted by TIS adherence. CONCLUSION: Model results suggest that increasing the use of TIS decreases medical care costs due to decreased hospital admissions and the use of IV anti-PA antibiotics at the expense of higher drug costs.


Subject(s)
Cystic Fibrosis/drug therapy , Cystic Fibrosis/economics , Pseudomonas Infections/drug therapy , Pseudomonas Infections/economics , Pseudomonas aeruginosa , Tobramycin/administration & dosage , Tobramycin/economics , Administration, Inhalation , Adolescent , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/economics , Anti-Bacterial Agents/therapeutic use , Child , Cystic Fibrosis/microbiology , Disease Progression , Female , Humans , Male , Managed Care Programs/economics , Models, Economic , Patient Admission/economics , Patient Admission/trends , Tobramycin/therapeutic use , United States
2.
Pharmacoeconomics ; 28(9): 751-64, 2010.
Article in English | MEDLINE | ID: mdl-20623994

ABSTRACT

BACKGROUND: Bipolar I disorder (BPD I) is a recurrent illness that affects 1% of the US population and constitutes a large economic burden. However, few studies have investigated the cost effectiveness of maintenance treatment options for BPD I. OBJECTIVE: To determine the cost effectiveness of maintenance treatment with quetiapine fumarate extended-release (XR) tablets in combination with mood stabilizers (lithium or divalproex) in comparison with the following treatments: placebo in combination with lithium or divalproex; no maintenance treatment; lithium monotherapy; lamotrigine monotherapy; olanzapine monotherapy; and aripiprazole monotherapy. METHODS: The analysis was conducted from the societal and payer perspectives in the US, using a Markov model. The model simulated a cohort of 1000 stabilized BPD I patients and estimated the quarterly risk in three health states: euthymia, mania and depression. Efficacy data were derived from two randomized, double-blind trials comparing quetiapine + lithium/divalproex with placebo + lithium/divalproex for up to 2 years, as well as other published literature. Resource data were extracted from published literature. Drug costs, hospitalizations and physician visits were among the direct costs. Indirect costs included absenteeism, and mortality rates included suicide. Benefits and costs were discounted at 3% and the price reference year was 2009. Endpoints included number of acute mood episodes, hospitalizations due to an acute mood event and costs per QALY. Probabilistic sensitivity analysis (PSA) was conducted to evaluate uncertainty in the model inputs. RESULTS: Treatment with quetiapine XR + lithium/divalproex was associated with reductions in acute mania (46%), acute depression (41%) and related hospitalizations (44%) compared with placebo + lithium/divalproex, and similar reductions in events were observed relative to lithium monotherapy. In the base-case analysis from the payer perspective, the discounted incremental cost per QALY for quetiapine XR + lithium/divalproex compared with placebo + lithium/divalproex was $US22 959, and compared with lithium monotherapy was $US100 235, while all other comparators were dominated. PSA showed these results to be robust to select assumptions. CONCLUSIONS: Quetiapine XR + lithium/divalproex may be a cost-effective maintenance treatment option for patients with BPD I.


Subject(s)
Antimanic Agents/economics , Antimanic Agents/therapeutic use , Bipolar Disorder/drug therapy , Bipolar Disorder/economics , Dibenzothiazepines/economics , Dibenzothiazepines/therapeutic use , Models, Economic , Absenteeism , Antimanic Agents/administration & dosage , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/economics , Antipsychotic Agents/therapeutic use , Aripiprazole , Benzodiazepines/administration & dosage , Benzodiazepines/economics , Benzodiazepines/therapeutic use , Bipolar Disorder/mortality , Cost-Benefit Analysis , Delayed-Action Preparations/economics , Dibenzothiazepines/administration & dosage , Drug Therapy, Combination/economics , Fees, Pharmaceutical , Health Care Costs , Hospital Charges , Humans , Lamotrigine , Lithium Compounds/administration & dosage , Lithium Compounds/economics , Lithium Compounds/therapeutic use , Markov Chains , Olanzapine , Piperazines/administration & dosage , Piperazines/economics , Piperazines/therapeutic use , Quality-Adjusted Life Years , Quetiapine Fumarate , Quinolones/administration & dosage , Quinolones/economics , Quinolones/therapeutic use , Risk , Tablets , Triazines/administration & dosage , Triazines/economics , Triazines/therapeutic use , United States , Valproic Acid/administration & dosage , Valproic Acid/economics , Valproic Acid/therapeutic use
3.
J Med Econ ; 12(4): 259-68, 2009.
Article in English | MEDLINE | ID: mdl-19769548

ABSTRACT

BACKGROUND: Bipolar I disorder is a recurrent illness that affects 1% of the US population and constitutes a large economic burden. Few studies have investigated the cost-effectiveness of maintenance treatment options. The objective of this analysis was to assess the cost-effectiveness of quetiapine (QTP) in combination with lithium (Li) or divalproex (DVP) compared with that of Li or DVP alone for maintenance treatment of bipolar disorder. METHODS: The cost-effectiveness of maintenance treatment with QTP in combination with Li or DVP was compared with placebo (PBO) in combination with Li or DVP from a US direct costs perspective using a Markov model. The model simulated a cohort of 1,000 stabilized patients with bipolar I disorder and estimated the quarterly risk in three health states: euthymia, mania, and depression. Efficacy data were derived from two randomized, double-blind, placebo-controlled trials comparing QTP + Li/DVP with PBO + Li/DVP for up to 2 years. Resource data were obtained from published literature. Direct costs included drug costs, hospitalizations, and physician visits. Outcomes and costs were discounted at 3% and the price reference year was 2007. Endpoints included the number of acute mood episodes, hospitalizations due to an acute mood event, and costs per quality-adjusted life-years. A probabilistic sensitivity analysis (PSA) was conducted to evaluate uncertainty. RESULTS: In the base-case analysis, QTP + Li/DVP dominated PBO + Li/DVP. The PSA showed these results to be robust. In addition, treatment with QTP + Li/DVP was associated with reductions in acute manic episodes (46%), acute depressive episodes (41%), and related hospitalizations (44%) compared with PBO + Li/DVP. CONCLUSIONS: These analyses, based on two randomized clinical trials, suggest that QTP + Li/DVP is a cost-effective maintenance treatment option for patients with bipolar I disorder compared with Li or DVP alone.


Subject(s)
Bipolar Disorder/drug therapy , Bipolar Disorder/economics , Dibenzothiazepines/economics , Lithium Compounds/economics , Valproic Acid/economics , Adolescent , Adult , Aged , Anticonvulsants/economics , Anticonvulsants/therapeutic use , Antipsychotic Agents/economics , Antipsychotic Agents/therapeutic use , Cost-Benefit Analysis , Dibenzothiazepines/therapeutic use , Drug Therapy, Combination/economics , Female , Humans , Lithium Compounds/therapeutic use , Male , Markov Chains , Middle Aged , Quetiapine Fumarate , Severity of Illness Index , Valproic Acid/therapeutic use , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...